Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: From ASSERT to SUSTAIN and beyond

Belinda A. Di Bartolo, Daniel J. Scherer, Stephen J. Nicholls

Research output: Contribution to journalArticle

9 Citations (Scopus)


Increasing attention has focused on efforts to promote the biological activities of high-density lipoproteins (HDL) in order to reduce cardiovascular risk. Targeting apolipoprotein A-I (apoA-I), the major protein carried on HDL particles, represents an attractive approach to promoting HDL by virtue of its ability to increase endogenous synthesis of functional HDL particles. A number of pharmacological strategies that target apoA-I, including upregulation of its production with the bromodomain and extraterminal (BET) protein inhibitor RVX-208, development of short peptide sequences that mimic its action, and administration as a component of reconstituted HDL particles, have undergone clinical development. The impact of these approaches on cardiovascular biomarkers will be reviewed.

Number of pages6
JournalArchives of Medical Science
Issue number6
Publication statusPublished - 1 Dec 2016


  • Apolipoprotein A-I
  • Atherosclerosis
  • Clinical trials
  • Lipids
  • Risk factors

ASJC Scopus subject areas

  • Medicine(all)

Cite this